- 1D
- 1W
- 1M
- 1Y
- 5Y
- YTD
About 2Seventy Bio
2Seventy Bio, Inc. is a cell and gene therapy company. The Company is focused on the research, development, and commercialization of transformative treatments for cancer. Its approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop targeted cellular therapies for patients with cancer. It is advancing multiple preclinical and clinical programs in oncology. The Company's lead preclinical programs in B cell non-Hodgkin's lymphoma (B-NHL) and acute myeloid leukemia are illustrations of its multiplex approach applied to address the specific challenges of treating those cancers. It is developing bbT369 product candidate as a treatment for patients with B-NHL.
0.55%
Stock Analysis
